Paricalcitol Reduced Residual Renal Risk in Diabetic Nephropathy Patients

Major Finding: Of 281 patients randomized to receive either placebo, 1 mcg, or 2 mcg of paricalcitol for 24 weeks along with their usual care for diabetes and cardiovascular protection, those in the 2-mcg group had the greatest percentage change in geometric mean urinary albumin-to-creatinine ratio at final measurement during treatment (–20%, compared with –16% and –3% for the 1-mcg paricalcitol and placebo groups, respectively).

Data Source: The VITAL study, a randomized, placebo-controlled, double-blind multinational study of selective vitamin D receptor activation with paricalcitol in patients with type 2 diabetes and albuminuria.

Disclosures: The VITAL study was sponsored by Abbott. Dr. de Zeeuw disclosed that he has been a consultant for, and his institution has received honoraria from, Abbott, Amgen, AztraZeneca, Bristol-Myers Squibb, Novartis, Noxxon, Johnson & Johnson, Hemcue, and Merck Sharp & Dohme. Other study authors and/or their institutions have served as board members, consultants, or received honoraria, research, or other funding from Abbott, Watson, Merck, Novartis, AstraZeneca, Amgen, Daiichi Sankyo, and Roche. Five of the authors on the study are employed by Abbott and own stock and have stock options in Abbott.